Presentation-Paediatric onset multiple sclerpsis

Second line DMT with high efficacy • PARADIGMS study with FINGOLIMOD was associated with a lower rate of relapse and reduced accumulation of lesions on MRI over a 2-year period versus IFN beta-1a • In 2018, the FDA and the EMA approved the indication of fingolimod in children with relapsing MS Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiplesclerosis.N Engl J Med2018 DMT: disease-modifying therapy; EMA: European Medicines Agency; FDA: Food and Drug Administration Chitnis T, et al. N Engl J Med. 2018 Sep 13;379(11):1017-1027